Claims for Patent: 10,478,494

Summary for Patent: 10,478,494

Title:	FGFR/PD-1 combination therapy for the treatment of cancer
Abstract:	Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
Inventor(s):	Karkera Jayaprakash, Platero Suso Jesus, Verona Raluca, Lorenzi Matthew V.
Assignee:	ASTEX THERAPEUTICS LTD
Application Number:	US15079136
Patent Claims:	2. The method of claim 1 , wherein the evaluating step further comprises measuring an expression level of PD-L1 in a biological sample and wherein the second administering step comprises administering the FGFR inhibitor if:the biological sample has a PD-L1 expression corresponding to an H-score of about 0 to about 99; orthe biological sample has a PD-L1 expression level that is lower than a reference PD-L1 expression level.3. The method of or claim 1 , wherein the biological sample is blood claim 1 , lymph fluid claim 1 , bone marrow claim 1 , a solid tumor sample claim 1 , or any combination thereof.4. The method of claim 1 , wherein the cancer is lung cancer claim 1 , bladder cancer claim 1 , gastric cancer claim 1 , breast cancer claim 1 , ovarian cancer claim 1 , head and neck cancer claim 1 , esophageal cancer claim 1 , glioblastoma claim 1 , or any combination thereof.5. The method of claim 4 , wherein the lung cancer is non-small cell lung cancer (NSCLC) adenocarcinoma claim 4 , NSCLC squamous cell carcinoma claim 4 , small cell lung cancer claim 4 , or any combination thereof.6. The method of claim 1 , wherein the one or more FGFR variants further comprise an FGFR mutation claim 1 , an FGFR amplification claim 1 , or a combination thereof.7. The method of claim 1 , wherein the antibody that blocks an interaction between PD-1 and PD-L1 is an anti-PD-1 antibody claim 1 , an anti-PD-L1 antibody claim 1 , or a combination thereof.8. The method of claim 2 , wherein the cancer is lung cancer claim 2 , bladder cancer claim 2 , gastric cancer claim 2 , breast cancer claim 2 , ovarian cancer claim 2 , head and neck cancer claim 2 , esophageal cancer claim 2 , glioblastoma claim 2 , or any combination thereof.9. The method of claim 8 , wherein the lung cancer is non-small cell lung cancer (NSCLC) adenocarcinoma claim 8 , NSCLC squamous cell carcinoma claim 8 , small cell lung cancer claim 8 , or any combination thereof.10. The method of claim 2 , wherein the one or more FGFR variants further comprise an FGFR mutation claim 2 , an FGFR amplification claim 2 , or a combination thereof.11. The method of claim 2 , wherein the antibody that blocks an interaction between PD-1 and PD-L1 is an anti-PD-1 antibody claim 2 , an anti-PD-L1 antibody claim 2 , or a combination thereof.12. The method of claim 3 , wherein the cancer is lung cancer claim 3 , bladder cancer claim 3 , gastric cancer claim 3 , breast cancer claim 3 , ovarian cancer claim 3 , head and neck cancer claim 3 , esophageal cancer claim 3 , glioblastoma claim 3 , or any combination thereof.13. The method of claim 12 , wherein the lung cancer is non-small cell lung cancer (NSCLC) adenocarcinoma claim 12 , NSCLC squamous cell carcinoma claim 12 , small cell lung cancer claim 12 , or any combination thereof.14. The method of claim 3 , wherein the one or more FGFR variants further comprise an FGFR mutation claim 3 , an FGFR amplification claim 3 , or a combination thereof.15. The method of claim 3 , wherein the antibody that blocks an interaction between PD-1 and PD-L1 is an anti-PD-1 antibody claim 3 , an anti-PD-L1 antibody claim 3 , or a combination thereof.16. The method of claim 1 , wherein the biological sample:has a PD-L1 expression corresponding to an H-score of less than 20; orhas a PD-L1 expression level that is lower than a reference PD-L1 expression level.17. The method of claim 16 , where the biological sample has a PD-L1 expression corresponding to an H-score of less than 20.